With an ageing population, it is increasingly common to encounter patients on anticoagulation or antiplatelet therapy in our practices.
threatening peri-operative haemorrhage associated with continuation of therapy is of immediate concern to the surgeon, the risk of a lifethreatening thromboembolic event from discontinuation of therapy is no less real for the patient. There are no substantial guidelines and no current consensus regarding the peri-operative management of anticoagulation or antiplatelet therapy of patients undergoing VR surgery. Therefore, the onus falls on the surgeon to weigh up the risks, consult with the physician involved in the care of antithrombotic therapy and discuss the decision with the patient. 
Current Practice

Indications for Antithrombotic Therapy
Warfarin is indicated in a variety of potentially life-threatening medical conditions including atrial fibrillation (AF), valvular heart disease, prosthetic valves, ischaemic heart disease, recurrent venous thromboembolism and hypercoagulable states. 
Evidence for Continuation or Cessation of Antithrombotic Therapy in Vitreoretinal Surgery
Although there was some controversy in earlier series as to whether warfarin and aspirin increase the risk of haemorrhage in intraocular surgery, 14 there was no compelling evidence to support the cessation of anticoagulation prior to surgery. [15] [16] [17] In fact, recent evidence suggests that it is safe to continue anticoagulation during VR procedures.
18,19
Narendran and Williamson 14 examined a series of 541 consecutive patients undergoing VR surgery, 60 of whom were on aspirin and seven of whom were on warfarin. One of 11 choroidal haemorrhages was on warfarin and one of nine rebleeds for diabetic vitrectomy was on warfarin. They concluded that aspirin has no effect on bleeding, but warfarin was associated with bleeding complications, so it is recommended that warfarin be stopped if the patient's risk profile is low.
In a series of 50 ophthalmic procedures, McCormack 15 et al. found no significant ocular haemorrhagic complications in the eight patients undergoing VR surgery and recommended that surgery can be safely performed while the patient is therapeutically anticoagulated. Saitoh et al. 16 described four patients undergoing vitrectomy and three undergoing scleral buckling in a large series of anterior segment surgery. They concluded that discontinuing anticoagulation was unnecessary for patients with life-threatening conditions. Gainey et al. 17 reviewed 50 patients undergoing ocular surgery on warfarin therapy, six of whom had VR surgery, and found no significant difference in haemorrhagic complications among patients in whom warfarin was continued and those in who it was discontinued. 
Risk of Stopping Antithrombotic Therapy
In a survey by Stone et al. 25 of 100 cataract surgeons who discontinued warfarin treatment before cataract surgery, six patients had acute strokes, two of which led to death, in addition to one patient who had a DVT and another who had a pulmonary embolus. In a survey of 57 physicians who discontinued anticoagulant therapy in the pre-operative period, Kapusta and warfarin was withheld and 39% when aspirin was discontinued.
Thrombotic events included 24 strokes, three cerebral emboli, five
MIs, eight transient ischaemic attacks (TIAs), three DVTs, two pulmonary emboli and one retinal artery occlusion leading to blindness. Three deaths were reported. 27 Several other series have also reported life-threatening thromboembolic events that have been related temporally to the peri-operative discontinuation of both aspirin and warfarin. [28] [29] [30] [31] Cessation of oral anticoagulation has been noted to cause a paradoxical state of hypercoagulability secondary to rebound effect, postulated to be related to interruption of the equilibrium between vitamin-K-dependent factors and proteins C and S.
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Similarly, the surgical milieu has been found to induce a hypercoagulable state including increased levels of plasminogen-
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activator inhibitor 1. 35, 36 Therefore, the necessity of stopping anticoagulation for surgery with an inherently low haemorrhagic risk is questionable.
Recent reports have shown that in patients with CAD, premature withdrawal of antiplatelet agents may lead to an increased rate of recurrence of events. Interruption of dual-platelet therapy soon after stent implantation increases the risk of acute stent thrombosis, with mortality varying from 15 to 45% in the first month. In addition, interruption of antiplatelet agents long after implantation of DES may expose the patients to late stent thrombosis. Similarly, interruption of dual antiplatelet treatment soon after the acute phase of non-ST elevation acute coronary syndromes (NSTE-ACS) may expose patients to a high risk of recurrent events, even in non-stented patients. 37 There have even been case reports, albeit few, resulting in death from stent thrombosis shortly after interruption of combined therapy for elective surgery.
38,39
Important Considerations
Risk of Haemorrhagic Complications
The majority of VR procedures can be safely performed without 
Conclusion
Current evidence provides a compelling argument for maintenance of anticoagulation and antiplatelet therapy during VR surgery. If required in selected cases, modification of anticoagulation or antiplatelet therapy must be undertaken in conjunction with the patient's physician to allow full comprehension of the systemic thromboembolic risks and ensure safe peri-operative management of antithrombotic therapy. n
